

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 May 2024 (23.05.2024)



(10) International Publication Number
WO 2024/107555 A1

(51) International Patent Classification:

C07D 471/00 (2006.01) A61K 31/435 (2006.01)
C07D 221/18 (2006.01) A61P 37/02 (2006.01)

(21) International Application Number:

PCT/US2023/078633

(22) International Filing Date:

03 November 2023 (03.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/425,442 15 November 2022 (15.11.2022) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, INDIANAPOLIS, Indiana 46285 (US).

(72) Inventors: **BELL, Michael**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **CALVIN, Joel**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **CARSON, Cheryl**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **CHAU-VIGNE-HINES, Lacie**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **CLARKE, Christian**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **DORSEY, Frank**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **GERNERT, Douglas**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **GREEN, Steven**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **MCMILLEN, William**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **NAVARRO, Antonio**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **RIZZO, John**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **LI, Shenshen** et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: AHR AGONISTS

(57) Abstract: The present disclosure relates to certain AHR agonist compounds, their method of making, and to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases, such as psoriasis and atopic dermatitis.

WO 2024/107555 A1